Kura Oncology (KURA), in collaboration with Kyowa Kirin, has received U.S. FDA approval for ziftomenib, branded as Komzifti, a treatment for adults with relapsed or refractory acute myeloid leukemia (AML) with specific genetic mutations. This approval follows the drug's priority review status, with a target action date previously set for November 30. Kura's CEO highlighted the company's readiness to commercialize the drug, supported by a strong financial position and partnership with Kyowa Kirin.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.